Poor 1Q25 with close to zero OP, slight improvement in 2Q but risks of restructuring and high inventories. Consensus expects slow recovery, stock is cheap at 11x 2026 EPS but wait one more quarter.
What is covered in the Full Insight:
Introduction
1Q25 Performance Analysis
2Q25 Expectations
Restructuring Plans
Valuation and Risks
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.